Clinical Department of Pediatrics IV, Division of Neonatology, Neuropediatrics and Inherited Metabolic Diseases, Medical University of Innsbruck, Innsbruck, Austria.
Wien Klin Wochenschr. 2009;121(23-24):746-9. doi: 10.1007/s00508-009-1280-x.
Ludwig Haberlandt (1 February 1885 - 22 July 1932), pioneer in hormonal contraception, was born in Graz, where he graduated from the university in 1909 in medicine summa cum laude and began his career as a physiologist. The idea of temporary hormonal contraception in the female body entered his mind in February 1919, when he was already Professor of Physiology in Innsbruck. He pursued his project ambitiously and by 1921 demonstrated temporary hormonal contraception in a female animal by transplanting ovaries from a second, pregnant, animal. From 1923, after further successful scientific work in this field, he began highlighting the importance of clinical trials in presentations. From then, he was criticized by his colleagues, who accused him of hindering unborn life. His idea was contradictory to the moral, ethic, religious and political agendas of that time in Europe. In 1927 official reports escalated, his family was ostracized by the local population, and Ludwig Haberlandt refused any further interviews. Against all opposition, in 1930 he began clinical trials after successful production of a hormonal preparation, Infecundin, by the G. Richter Company in Budapest, Hungary. Although at the peak of his scientific career, he was unable to pursue other scientific agendas because of the disputed contraception project. After he committed suicide, on 22 July 1932, scientific discussion about hormonal contraception ceased until 1970 when scientists began referring to his earlier medical and scientific work.
路德维希·哈伯兰(Ludwig Haberlandt)(1885 年 2 月 1 日-1932 年 7 月 22 日),激素避孕的先驱,出生于格拉茨,1909 年在那里以优异成绩毕业于大学,并开始了他的生理学家生涯。1919 年 2 月,当他已经在因斯布鲁克担任生理学教授时,他就有了在女性体内进行临时激素避孕的想法。他雄心勃勃地追求这个项目,到 1921 年,他通过将第二个怀孕动物的卵巢移植到雌性动物身上,证明了在雌性动物中进行临时激素避孕的效果。从 1923 年开始,在该领域的进一步成功科学工作之后,他开始在演讲中强调临床试验的重要性。从那时起,他就受到了同事们的批评,他们指责他阻碍了未出生的生命。他的想法与当时欧洲的道德、伦理、宗教和政治议程相悖。1927 年,官方报告升级,他的家人被当地居民排斥,路德维希·哈伯兰特拒绝接受任何进一步的采访。尽管他在科学界处于巅峰时期,但由于有争议的避孕项目,他无法追求其他科学议程。1930 年,在匈牙利布达佩斯的 G. Richter 公司成功生产出一种激素制剂 Infecundin 后,他不顾所有反对意见,开始进行临床试验。尽管他处于科学事业的巅峰,但由于有争议的避孕项目,他无法继续进行其他科学议程。1932 年 7 月 22 日,他自杀后,关于激素避孕的科学讨论停止了,直到 1970 年,科学家们开始参考他早期的医学和科学工作。